WHO Expert Committee on Leprosy has recommended combined chemotherapy for both multi bacillary and paucibacillary leprosy cases with an objective of preventing the multiple drug resistance consequent to emergence of wide-spread dapsone resistance (both primary and secondary). It has also been demonstrated that daily administration of 600 mg rifampicin is not more effective than monthly administration of 600 mg on consecutive days.8
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To what extent dapsone and c10fazimine can affect rifampicin pharmacokine tics has not been studied in cases of multi bacillary and paucibacillary leprosy.
Objectives of the present study
With the fo llowing three objectives, the present study was initiated:
To determine to what extent the type of leprosy (multibacillary and paucibacillary) can influence pharmacokinetic parameters of rifampicin. 2 To study the influence of fo llowing three regimens on the pharmacokinetic parameters of rifampicin (within comparison): (a) rifampicin + dapsone + c1ofa zimine (RDC); (b) rifampicin + dapsone (RD); and (c) rifampicin + c10fazimine (RC). 3 To determine differences in pharmacokinetic parameters of rifampicin within the above three groups, i.e. in between comparison; RDC vs RD; RDC vs RC; and RD vs RC).
Materials and methods

SUBJECTS
Male leprosy cases in the age group of 15-60 years were selected. Selection criteria used are enumerated below:
1 In clusion. a, non-obese patients; b, a confirmed case of multi bacillary or paucibacillary leprosy; and c, should not have received any other drugs for at least 2 weeks prior to initiation of the study.
2 Exclusion. a, History of allergy to any one of the drugs in study period, i.e. rifampicin, dapsone and c1ofazimine; b, patients having any gastrointestinal ulcers and history of gastrectomy; c, patients requiring any other concomitant therapy; and d, patients with any other disease, haematological, renal, cardiovas cular or hepatic.
Plan and design
METHOD
Complete double blind within comparison design was used. A minimum time span of 2 weeks between doses, after an initial 'run in' period of one week, was kept. The allocation of drug regimen was based on nature of leprosy. Specimens were code labelled as per master code sheet. Details of experimental design are given in Table 1 .
DOSAGE
'Run in ' period. The patients were divided into three groups of six patients each. Physical examination (height, weight and midarm muscle circumference) and laboratory investigations such as bacteriological index, nasal smear, blood (total and differential WBC counts, haemoglobin, haematocrit, bleeding time, coagulation time and platelet count), urine, stool and sputum examination, liver fu nction tests (SGOT, SGPT, alkaline phosphatase and serum bilirubin), were carried out and recorded in the proforma. No drugs were given during this period of one week.
Pre-dose period. Patients were fa sted overnight for 8 hr prior to the day of estimating the drug levels. One hour prior to the study, 250 ml of water was given to each of them. They were asked to void urine 15 min prior to the dose administration.
Dosing. Both multibacillary and paucibacillary cases received 600 mg rifampicin alone at the exact time of drug administration. The time at which rifampicin had been given was recorded for each of the patients.
Post-dosing period. The cases were not given any fo od during the next 3 hr of the study, but 150 ml of water was given at the end of 1 and 2 hr. No strenuous or athletic activity was permissible during the period of study. A light breakfast was given 3 hr after the study, i.e. at 12.15 pm.
PHARMACOKINETIC SAMPLING
A siliconized intravenous catheter was used for withdrawing 3 ml of blood in a 15 ml code labelled centrifuge tube at 9.00 am, 10.00 am, 11.00 am, 1.00 pm and 3.00 J Mehta pm on the first day and 9.00 am on the next day; i.e. 0, 1, 2,4,6 and 24 hr blood samples were collected. Any deviations fr om the stated sampling times were recorded on the fo rm. For withdrawing blood, Medivik disposable sterile syringes were used. The code labels and code letters were selected by the investigator for each case.
The separated serum was transferred to code labelled vials. The vials were sealed with aluminium seals by a hand-sealing machine. Until the time of transportation, they were kept in a Thermos with ice in the refrigerator. On the day of transportation, they were taken in the Thermos flask. On the same day the microbiological assay of rifampicin was done by the USP method.
STATISTICAL ANALYSIS
U sing a single compartment pharmacokinetic model the values of Ka, Ke, Auc, avd-k g, MRC, ti tp., Cmax and Auc/ti were calculated. Mean and standard error for the pharmacokinetic parameters were calculated. Student's 't' test (two tailed) was used for 'in between comparison' and paired 't' test was used for 'within comparison'.
Results
COMPARISON OF PHARMACOKINETIC PARAMETERS IN MULTIBACILLARY AND PAUCIBACILLAR Y LEPROSY CASES
No statistically significant difference was noted in rifampicin pharmacokinetic parameters, like Ka, Ke, Auc, avd-k g, tp, MCR, ti, Cmax and Auc/ti in multibacillary and paucibacillary leprosy cases. Apparently the type of leprosy has no effect on rifampicin pharmacokinetics.
EFFECT OF DIFFERENT REGIMENS ON THE RIFAMPICIN PHARMACOKINE TICS (WITHIN COMPARISON)
The following observations were noted: RC Group. While comparing 'within patient' data for the pre-and post regimen phases of RC group, clofazimine was fo und to reduce the rate of absorption (Ka) of rifampicin (P < 0·01) and delay the time to reach the peak serum concentration (tp) (P < 0·01). However, no statistically significant differ ence was noted in other pharmacokinetic parameters, i.e. Ke, Auc, avd-k g, MCR, ti, Cmax and Auc/ti ratio. 2 RDC Group. Except for reducing Auc (P < 0·05), no statistically significant difference in other pharmacokinetic parameters of rifampicin, i.e. Ka, Ke, avd-k g, MCR, ti, tp, Cmax and Auc/ti ratio was noted in group RDC. However, 1 h 
NB, n, number of patients; ROC, rifampicin + dapsone + clofazimine; RO, rifampicin + dapsone; RC, rifampicin + clofazimine; values are expressed as mean ± SE. * P<O·05. Paired 't' test used for 'within comparison' serum concentration of rifampicin was significantly reduced in RDC group (P < 0'05) in post-regimen phase. 3 RD Group. No statistically significant alteration in any of the pharmacokine tic parameters of rifampicin was noted in group RD.
COMPARISON OF PHARMACOKINETIC PARAMETERS OF RIFAMPICIN IN PRE AND POST-THERAPY PHASES IN VARIOUS GROUPS (IN BETWEEN COMPARI SON)
While comparing the three groups ('in between patient' data), no statistically significant difference was noted when RDC was compared with RD. In the post regimen phase of RC, the fo llowing statistically significant differences in pharma co kinetic parameters of rifampicin were seen as compared to RDC:
(a) The rate of elimination of rifampicin in RC was significantly less than in the RDC (P < 0'05). (b) The metabolic clearance rate of rifampicin in RC was significantly less than in the RDC (P < 0·02) (c) The tt of rifampicin in RC was significantly more than in the RDC (P < 0·02) (d) The Auc/ tt ratio of rifampicin was significantly more in the pre-regimen phase 1·86  2·06  0·0046  0·0059  4·51  3·44  ±0·38  ±0·79  ±0·0006  ±0·0009  ±0-41  ±0·30  RD  5  1·79  1·59  0·0048  0·0049  4·66  3·64  ±0·1O  ±0·33  ±0·0009  ±0·0009  ±0·55  ±0·35  RC  5  1·27  1·47  0·0037  0·0040  3·80  4·23  ±0·16  ±O·II  ±O·O  ±0·0002  ±0·36 of RC than in RDC (P < 0·05); while mean Aucj ti-ratio was less in 'post-regimen phase' of RC than 'pre-regimen phase' value and the 'post regimen' mean Aucjt i ratio was more in RD than the 'pre-regimen phase' value; but no statistically significant difference was noted. While dapsone showed the tendency to increase Aucjt i-ratio, clofazimine reversed this tendency and the overall effect in the RDC group was the tendency to reduce Aucjt i-ratio.
2 While comparing pre-regimen phases of RD with RC, the fo llowing , statistically significant differences were noted:
(a) The rate of absorption of rifampicin was significantly less in RC than in RD (P < 0·05).
(b) The apparent volume of distribution of rifampicin was significantly more in RD than in RC (P < 0'001). The avd ( l /k g ) was also significantly different in the same way (P < 0·01).
3 Similar comparison of post-regimen phase of RD with RC, fo llowing changes in the pharmacokinetic parameters of rifampicin were noted:
(a) The rate of absorption of rifampicin was fu rther significantly reduced in RC than in RD. The degree of statistical significance was also increased (P < 0·05 to P<O·Ol).
(b) While the avd in RD regimen reduced fr om 93·74±4·13 to 81·74 ± 15'52, it increased in RC regimen from 64·69 ± 6·06 to 78·88 ± 10·56. Hence no statistically significant difference was noted.
(c) The time to reach peak serum concentration (tp) was significantly more in RC than in RD (P < 0,01). The ti-was also increased though not significantly statistically.
(d) While Cmax increased in RD regimen fr om 6·15 ± 0·26 to 8·01 ± 2·3 it declined in RC from 7·32 ± 0·25 to 6·23 ± 0·66. A similar trend was seen in Aucjt i-ratio. Hence no statistically significant difference was noted.
Discussion
In the present study, rifampicin pharmacokinetics was not affected by the type of leprosy. However, it is evident that the absorption of rifampicin was relatively less than that seen in healthy human volunteers. Whether it is due to reduced gastrointestinal absorption due to the disease per se or due to lower levels of plasma proteins is difficult to say due to the paucity of data for these assumptions.
Viratenen & Tala (1974f have reported that prolonged treatment increases the rate of inactivation or elimination of rifampicin. Since rifampicin has been given only as a single dose, the possibility of it per se increasing the rate of its inactivation or elimination is ruled out.
Dapsone did not affect the rifampicin bioavailability, and this finding is J Mehta consistent with experimental observations in mice where no evidence of any antagonism between dapsone and rifampicin has been demonstrated. 5 Rifampi cin is capable of increasing the rate of clearance of dapsone fr om plasma, possibly secondary to the induction of hepatic microsomal enzymes that may increase N hydroxylation (which is microsome dependent) instead of increasing the acetylation of dapsone.2,3 Furthermore, the levels of dapsone achieved in blood by means of daily doses of 50-100 mg are far too high to be reduced to subtherapeutic levels by sustained daily treatment with rifampicin. Clearly then, the employment of a once monthly schedule of rifampicin administration exerts little if any effect on the rate of dapsone clearance. In the present study the levels of dapsone were not estimated, but it can be safely concluded that regular dapsone administration did not alter the rifampicin pharmacokinetic parameters. Thus concomitant combined regimen of dapsone with rifampicin does not pose a pharmacokinetic drug interaction problem in the management of leprosy patients.
To what extent single administration of rifampicin and daily administration of dapsone can influence clofazimine levels in leprosy cases has not been studied in the present study, but effect of dapsone and clofazimine alone and in combination has been assessd on the rifampicin pharmacokinetic parameters.
Except for significant reduction in Ka (P < 0'01) and an increase in tp (P < 0'05) in RC group and significant reduction in I-hr serum rifampicin level (P < 0·05) and Auc (P < 0'05) in RDC group, no other statistically significant alterations were produced perhaps due to opposing trends in other parameters.
Although not statistically significant, two basic opposing trends were observed. While clofazimine showed the tendency of increasing the apparent volume of distribution coupled with a tendency to reduce the rate of elimination, dapsone exerted an opposing influence. Since clofazimine reduced Ka signifi cantly in addition to the trend of increasing avd and MCR, the logical outcome should have been a reduction in ti-and Auc, but on the contrary a trend of increase was noted, perhaps best explained by the trend of reducing the rate of elimination.
On the other hand, dapsone reversed the trends in the opposite direction. A trend of reduced apparent volume of distribution associated with a tendency to increase the rate of elimination was seen. Thus the fo rmer resulted in a trend of increase in Cmax and Auc of rifampicin, while the latter, in addition to an increase in MCR, accounted for a trend of increase in ti of rifampicin; thus overall effect was negligible.
Consequent to these opposing influences, combined effect of dapsone and clofazimine resulted in a trend of reduction in Ka and increase in tp of rifampicin. Added to this was the trend of an increase in MCR, avd and Ke accounting for the tendency of decrease in Cmax and t i-and overall statistically significant reduction in Auc (P < 0'05).
Of the three groups, both RDC and RD were homogenous groups. Auc/ti ratio of rifampicin in RC group was comparatively higher than in RDC (P < 0·05) and RD group (P < 0·001). While comparing with RD group rifampicin avd and Ka were relatively less (P < 0·001; P < 0·05 respectively) in RC group, the fo rmer resulting in increased Cmax (P < 0·01) despite a reduced Ka and thus resulting in an increased Auc/tt ratio even in the pre-regimen phase (P <O·Ol).
On the other hand except for Auc/ tt ratio (P < 0·05), both RDC and RC groups were homogenous in the pre-regimen phase. And in post-regimen phase while clofazimine showed the tendency of reducing rifampicin Ka (P < 0·05) and increasing MCR (P < 0·02), dapsone was fo und to increase both the parameters. And this effect predominated even when dapsone was used concomitantly with clofazimine; thus RDC differed significantly fr om RC in these respects. Ultimately, it resulted in a prolonged tt in RC group significantly different from RDC group (P < 0·02).
Conclusions
Clofazimine reduced rifampicin absorption significantly resulting in delayed time to reach peak serum concentration and increased tt, but no significant change was seen in Auc, and Cmax because Ke was reduced significantly by clofazimine when used without dapsone in addition to insignificant increase in MCR.
Obviously, fu rther studies are required to determine the time interval to be kept between administration of clofazimine and rifampicin so that it may not interfere with the absorption of rifampicin. In view of this, the fo llowing questions were raised: (a) Whether it is appropriate to give clofazimine daily when it is known to have a long half life. (b) Whether it would be rational to combine the monthly supervised dose of clofazimine (300 mg) with rifampicin (600 mg) in the light of the present findings. In view of this, whether it would be appropriate to increase the monthly dose of rifampicin to compensate for the 'clofazimine effect'.
Some clinical impressions of Multidrug therapy (MDT) in leprosy
The Poona District Leprosy Committee is running two leprosy control projects, one in the urban area of Po on a and the other at Solapur. In these projects, by the end of December 1985, 4532 leprosy patients were given MDT. Of these, 1828 patients are multibacillary while 2704 are paucibacillary.
-
The standard regimen recommended by the WHO Technical Report Series 6759 is being fo llowed for multibacillary as well as paucibacillary cases. The patients who have maintained regularity in treatment have shown clinical as well as bacteriological improvement. They did not show major side-effects/toxicity. A detailed analysis of the data is being undertaken. However, a fe w cases in whom interesting clinical findings were observed are reported here.
In 21 multibacillary cases, the bacteriological index started falling initially and after it dropped to 1'0/1'5 it remained static, even after continuing MDT, though they showed definite clinical improvement. The pigmentary changes and the ichthyotic changes seen during clofazimine therapy persist for more than 2 years after stopping clofazimine. In a few patients, pigmentation due to clofazimine therapy is not pronounced, though supervised clofazimine therapy is confirmed. The reason for this is not known.
In 20 paucibacillary patients, those previously treated with dapsone monoth erapy and later put on MDT did not show much clinical improvement in respect of the patches, while clinical response in new untreated paucibacillary patients treated with MDT is excellent, as observed in the disappearance of the patches. It is the observation of some of our colleagues that if MDT is discontinued after 6 months, patients report back within 1 year with relapse in the fo rm of new patches.
